Search

everythinglearnresearchcommunity

for

Search:↓

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Janus kinase inhibitors may help treat lichen planopilaris.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Certain mutations in the KLHL24 gene cause a skin disorder by breaking down an important skin protein.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Axitinib treatment turned a man's grey hair back to black.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.

Suppressing ODC activity reduces tumor growth in hair follicles.

Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.